Relations between personality changes and cerebrospinal fluid biomarkers of Alzheimer's disease pathology

被引:22
|
作者
Tautvydaite, D. [1 ]
Antonietti, J. P. [2 ]
Henry, H. [3 ]
von Gunten, A. [1 ]
Popp, J. [1 ]
机构
[1] Lausanne Univ Hosp CHUV, Serv Old Age Psychiat, Dept Psychiat, Lausanne, Switzerland
[2] Univ Lausanne, Inst Psychol, Lausanne, Switzerland
[3] Lausanne Univ Hosp CHUV, Serv Biomed, Lausanne, Switzerland
基金
新加坡国家研究基金会;
关键词
Personality changes; Cerebrospinal fluid biomarkers; Revised NEO Personality Inventory (NEO-PI-R); Alzheimer's disease (AD); Mild cognitive impairment (MCI); MILD COGNITIVE IMPAIRMENT; DEMENTIA; DIAGNOSIS; RISK; AGE; ASSOCIATIONS; RELIABILITY; CONSENSUS; OLDER;
D O I
10.1016/j.jpsychires.2016.12.024
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Specific changes in personality profiles may represent early non:cognitive symptoms of Alzheimer's disease (AD). Evaluating the subject's personality changes may add significant clinical information, as well as help to better understand the interaction between personality change, cognitive decline, and cerebral pathology. With this study we aimed to describe the relationship between personality changes and cerebrospinal fluid (CSF) markers of AD pathology at early clinical stages of the disease. One hundred and ten subjects, of whom 66 cognitively impaired patients (57 with mild cognitive impairment (MCI), and 9 with mild dementia) and 44 healthy controls, had neuropsychological examination as well as lumbar puncture to determine concentrations of CSF biomarkers of AD pathology (amyloid beta(1-42) (A beta(1-42)), phosphorylated tau (ptau-181), and total-tau (tau)). The Revised NEO Personality Inventory (NEO-PI-R) was administered twice, once to evaluate subjects' current personality and once to assess personality traits retrospectively 5 years before evaluation. Subjects with an AD CSF biomarker profile showed significant increase in neuroticism and decrease in conscientiousness over time as compared to non-AD CSF biomarker group. In regression analysis controlling for global cognition as measured by the MMSE score, increasing neuroticism and decreasing extraversion, openness to experience and conscientiousness were associated with lower A beta(1-42) concentrations but not with tau and ptau-181 concentrations. Our findings suggest that early and specific changes in personality are associated with cerebral AD pathology. Concentrations of CSF biomarkers, additionally to severity of the cognitive impairment, significantly contribute in predicting specific personality changes. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:12 / 20
页数:9
相关论文
共 50 条
  • [1] Interaction between personality traits and cerebrospinal fluid biomarkers of Alzheimer’s disease pathology modulates cognitive performance
    Domilė Tautvydaitė
    Deepti Kukreja
    Jean-Philippe Antonietti
    Hugues Henry
    Armin von Gunten
    Julius Popp
    Alzheimer's Research & Therapy, 9
  • [2] Interaction between personality traits and cerebrospinal fluid biomarkers of Alzheimer's disease pathology modulates cognitive performance
    Tautvydaite, Domile
    Kukreja, Deepti
    Antonietti, Jean-Philippe
    Henry, Hugues
    von Gunten, Armin
    Popp, Julius
    ALZHEIMERS RESEARCH & THERAPY, 2017, 9
  • [3] Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers
    Bridel, Claire
    Somers, Charisse
    Sieben, Anne
    Rozemuller, Annemieke
    Niemantsverdriet, Ellis
    Struyfs, Hanne
    Vermeiren, Yannick
    Van Broeckhoven, Christine
    De Deyn, Peter P.
    Bjerke, Maria
    Nagels, Guy
    Teunissen, Charlotte E.
    Engelborghs, Sebastiaan
    BRAIN, 2022, 145 (11) : 4056 - 4064
  • [4] Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms
    Doecke, James D.
    Rembach, Alan
    Villemagne, Victor L.
    Varghese, Shiji
    Rainey-Smith, Stephanie
    Sarros, Shannon
    Evered, Lisbeth A.
    Fowler, Christopher J.
    Pertile, Kelly K.
    Rumble, Rebecca L.
    Trounson, Brett
    Taddei, Kevin
    Laws, Simon M.
    Macaulay, S. Lance
    Bush, Ashley I.
    Ellis, Kathryn A.
    Martins, Ralph
    Ames, David
    Silbert, Brendan
    Vanderstichele, Hugo
    Masters, Colin L.
    Darby, David G.
    Li, Qiao-Xin
    Collins, Steven
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 61 (01) : 169 - 183
  • [5] Cerebrospinal fluid biomarkers of Alzheimer’s disease
    Xiaojing Sui
    Jianjun Liu
    Xifei Yang
    Neuroscience Bulletin, 2014, 30 : 233 - 242
  • [6] Cerebrospinal fluid biomarkers in Alzheimer's disease
    Hugon, Jacques
    Dumurgier, Julien
    Cognat, Emmanuel
    Paquet, Claire
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2018, 202 (1-2): : 307 - 318
  • [7] Cerebrospinal fluid biomarkers of Alzheimer's disease
    Fagan, Anne M.
    Holtzman, David M.
    BIOMARKERS IN MEDICINE, 2010, 4 (01) : 51 - 63
  • [8] Cerebrospinal fluid biomarkers of Alzheimer's disease
    Sui, Xiaojing
    Liu, Jianjun
    Yang, Xifei
    NEUROSCIENCE BULLETIN, 2014, 30 (02) : 233 - 242
  • [9] Cerebrospinal fluid biomarkers in Alzheimer's disease
    Lee, K. H.
    JOURNAL OF NEUROCHEMISTRY, 2013, 125 : 41 - 42
  • [10] Cerebrospinal Fluid Biomarkers for Alzheimer's Disease
    Blennow, Kaj
    Zetterberg, Henrik
    JOURNAL OF ALZHEIMERS DISEASE, 2009, 18 (02) : 413 - 417